» Articles » PMID: 37892990

The Impact of Clinical and Histopathological Factors on Disease Progression and Survival in Thick Cutaneous Melanomas

Overview
Journal Biomedicines
Date 2023 Oct 28
PMID 37892990
Authors
Affiliations
Soon will be listed here.
Abstract

Thick cutaneous melanomas (Breslow depth > 4 mm) are locally advanced tumors, generally associated with poor prognosis. Nevertheless, these tumors sometimes display unpredictable behavior. This study aims to analyze clinical and histopathological features that can influence the prognosis of thick melanomas. This is a retrospective study on 94 thick primary cutaneous melanomas diagnosed between 2012 and 2018 that were followed-up for at least five years to assess disease progression and survival. We evaluated the age, gender, tumor location, histological subtype, Breslow depth, Clark level, resection margins, mitotic index, the presence/absence of ulceration, necrosis, regression, microsatellites, neurotropism, lymphovascular invasion, and the pattern of tumor-infiltrating lymphocytes, and their association with disease progression and survival. By conducting univariate analysis, we found that progression-free survival (PFS) was significantly associated with female gender, the superficial spreading melanoma (SSM) subtype, mitotic index, necrosis, microsatellites, and perineural invasion. Overall survival (OS) was significantly associated with female gender, Breslow depth, SSM subtype, necrosis, microsatellites, and perineural invasion. Through multivariate Cox proportional hazards regression, we found that the only factors associated with PFS were Breslow depth, necrosis, microsatellites, and perineural invasion, while the factors associated with OS were Breslow depth, necrosis, microsatellites, and perineural invasion. Certain histopathological features such as Breslow depth, necrosis, microsatellites, and perineural invasion could explain differences in disease evolution. This is one of the first studies to demonstrate an association between necrosis and perineural invasion and outcomes in patients with thick melanomas. By identifying high-risk patients, personalized therapy can be provided for improved prognosis.

Citing Articles

Area Deprivation Index and Melanoma Thickness in Veterans.

Moncayo A, Ferguson J, Dizon M, Huhmann L, Kim D, Do N JAMA Dermatol. 2025; .

PMID: 40047783 PMC: 11886871. DOI: 10.1001/jamadermatol.2025.0311.


RET Inhibitor SPP86 Triggers Apoptosis and Activates the DNA Damage Response Through the Suppression of Autophagy and the PI3K/AKT Signaling Pathway in Melanoma Cells.

Zhang Y, Liu H, Wang K, Zheng J, Luan H, Xin M Drug Des Devel Ther. 2025; 19():67-82.

PMID: 39803607 PMC: 11724630. DOI: 10.2147/DDDT.S473390.


Metastatic Nodular Melanoma with Angiosarcomatous Transdifferentiation-A Case Report and Review of the Literature.

Dumitru A, Tapoi D, Costache M, Ciongariu A, Ionescu A, Liscu H Diagnostics (Basel). 2024; 14(13).

PMID: 39001214 PMC: 11240390. DOI: 10.3390/diagnostics14131323.


The Prognostic Value of Proliferative Activity in Cutaneous Melanoma: A Pilot Study Evaluating the Mitotic Rate and Ki67 Index to Predict Patient Outcomes.

Tapoi D, Gheorghisan-Galateanu A, Gosman L, Derewicz D, Costache M Biomedicines. 2024; 12(6).

PMID: 38927524 PMC: 11202243. DOI: 10.3390/biomedicines12061318.


Role of a Polyphenol-Enriched Blueberry Preparation on Inhibition of Melanoma Cancer Stem Cells and Modulation of MicroRNAs.

Alsadi N, Yahfoufi N, Nessim C, Matar C Biomedicines. 2024; 12(1).

PMID: 38255297 PMC: 10813708. DOI: 10.3390/biomedicines12010193.


References
1.
Boada A, Tejera-Vaquerizo A, Requena C, Manrique-Silva E, Traves V, Nagore E . Association between melanoma thickness and clinical and demographic characteristics. Eur J Dermatol. 2021; . DOI: 10.1684/ejd.2021.4096. View

2.
Kobeissi I, Tarhini A . Systemic adjuvant therapy for high-risk cutaneous melanoma. Ther Adv Med Oncol. 2022; 14:17588359221134087. PMC: 9619267. DOI: 10.1177/17588359221134087. View

3.
Villani A, Potestio L, Fabbrocini G, Troncone G, Malapelle U, Scalvenzi M . The Treatment of Advanced Melanoma: Therapeutic Update. Int J Mol Sci. 2022; 23(12). PMC: 9223461. DOI: 10.3390/ijms23126388. View

4.
Cintolo J, Gimotty P, Blair A, Guerry D, Elder D, Hammond R . Local immune response predicts survival in patients with thick (t4) melanomas. Ann Surg Oncol. 2013; 20(11):3610-7. DOI: 10.1245/s10434-013-3086-3. View

5.
Chu P, Chen Y, Li C, Yang J, King Y, Chiu Y . Factors influencing locoregional recurrence and distant metastasis in Asian patients with cutaneous melanoma after surgery: A retrospective analysis in a tertiary hospital in Taiwan. J Chin Med Assoc. 2021; 84(9):870-876. DOI: 10.1097/JCMA.0000000000000586. View